The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy
Authors:
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 13, 440-452
Abstract
No abstract availableKeywords
Funding Information
- BioMarin Pharmaceutical
This publication has 37 references indexed in Scilit:
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophiliaGene Therapy, 2011
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transductionVirology, 2007
- Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapyBlood, 2006
- Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primatesBlood, 2006
- α2,3 and α2,6 N-Linked Sialic Acids Facilitate Efficient Binding and Transduction by Adeno-Associated Virus Types 1 and 6Journal of Virology, 2006
- Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patientsGene Therapy, 2000